Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference By: Renalytix plc via GlobeNewswire February 09, 2024 at 09:00 AM EST LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG. About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com. For further information, please contact: Renalytix plc www.renalytix.comJames McCullough, CEOVia Walbrook PR Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker)Tel: 020 7597 4000Gary Clarence / Shalin Bhamra Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Alice WoodingsMob: 07980 541 893 / 07407 804 654 CapComm Partners Peter DeNardoTel: 415-389-6400 or investors@renalytix.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference By: Renalytix plc via GlobeNewswire February 09, 2024 at 09:00 AM EST LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG. About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com. For further information, please contact: Renalytix plc www.renalytix.comJames McCullough, CEOVia Walbrook PR Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker)Tel: 020 7597 4000Gary Clarence / Shalin Bhamra Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Alice WoodingsMob: 07980 541 893 / 07407 804 654 CapComm Partners Peter DeNardoTel: 415-389-6400 or investors@renalytix.com
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG. About RenalytixRenalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com. For further information, please contact: Renalytix plc www.renalytix.comJames McCullough, CEOVia Walbrook PR Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker)Tel: 020 7597 4000Gary Clarence / Shalin Bhamra Walbrook PR LimitedTel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Alice WoodingsMob: 07980 541 893 / 07407 804 654 CapComm Partners Peter DeNardoTel: 415-389-6400 or investors@renalytix.com